Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®

• Main Authors: Laura Saint‐Lary (Author), Isabelle Lacroix (Author), Valériane Leroy (Author), Agnès Sommet (Author)
• Formato: Libro
• Publicado: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract In 2018, a significant neural tube defects (NTD) signal was reported after pre‐conceptional exposure to dolutegravir, but was not confirmed in further analysis. Since 2019, dolutegravir‐based regimen, an integrase inhibitor (INI), is recommended by WHO as the most‐effective first‐line thera...